-
Vestibular migraine: an update. Curr. Opin. Neurol. (IF 4.8) Pub Date : 2024-04-16 Maria D Villar-Martinez, Peter J Goadsby
We performed a narrative review of the recent findings in epidemiology, clinical presentation, mechanisms and treatment of vestibular migraine.
-
Pregnancy and reproductive health in women with multiple sclerosis: an update. Curr. Opin. Neurol. (IF 4.8) Pub Date : 2024-04-09 Maria K Houtchens
Multiple sclerosis (MS) is a chronic immune-mediated, inflammatory, neuro-degenerative disease of the central nervous system, prevalent in women of reproductive age. Today, many women want to start a family after MS diagnosis. There are over 20 treatments for MS, and safely navigating family planning is important. We review updated information on family planning, preconception, and peri-partum considerations
-
New knowledge on anti-IgLON5 disease. Curr. Opin. Neurol. (IF 4.8) Pub Date : 2024-04-02 Carles Gaig, Lidia Sabater
Anti-IgLON5 disease is characterized by a distinctive sleep disorder, associated with a heterogeneous spectrum of neurological symptoms. Initial autopsies showed a novel neuronal tauopathy predominantly located in the tegmentum of the brainstem. Recently, new diagnostic red flags, biomarkers predictors of response to immunotherapy, and novel insights into the autoimmune pathogenesis of the disease
-
Shifting our attention earlier in the multiple sclerosis disease course. Curr. Opin. Neurol. (IF 4.8) Pub Date : 2024-03-29 Samantha Epstein, Erin E Longbrake
Revisions of multiple sclerosis (MS) diagnostic criteria enable clinicians to diagnose patients earlier in the biologic disease course. Prompt initiation of therapy correlates with improved clinical outcomes. This has led to increased attention on the earliest stages of MS, including the MS prodrome and radiologically isolated syndrome (RIS). Here, we review current understanding and approach to patients
-
Bruton tyrosine kinase inhibitors in multiple sclerosis: evidence and expectations. Curr. Opin. Neurol. (IF 4.8) Pub Date : 2024-03-28 Julia Krämer, Heinz Wiendl
Despite availability of high-efficacy therapies for multiple sclerosis (MS), many patients experience significant disability worsening due to limited effects of currently available drugs on central nervous system (CNS)-compartmentalized inflammation. Bruton tyrosine kinase (BTK) is an intracellular signaling molecule involved in regulation of maturation, survival, migration, and activation of B cells
-
Understanding multiple sclerosis as a disease spectrum: above and below the clinical threshold. Curr. Opin. Neurol. (IF 4.8) Pub Date : 2024-03-28 Stephen Krieger, Karin Cook, Carrie M Hersh
Research in multiple sclerosis (MS) has long been predicated on clinical groupings that do not reflect the underlying biologic heterogeneity apparent within patient populations. This review explicates the various levels of explanation through which the spectrum of disease is described and investigated both above and below the clinical threshold of detection, as framed by the topographical model of
-
The state of art on the use of patient reported outcomes in migraine. Curr. Opin. Neurol. (IF 4.8) Pub Date : 2024-03-27 Alicia Alpuente, Marta Torres-Ferrus, Edoardo Caronna, Patricia Pozo-Rosich
This review aims to explore the use of patient-reported outcome measures (PROMs) in migraine. Traditionally assessed through specific features, recent adoption of PROMs allows for a more objective and quantifiable evaluation. PROMs, which are standardized questionnaires collecting health information directly from a patients' perspective, cover various aspects, including migraine specific aspects. The
-
Interest of rare autoantibodies in autoimmune encephalitis and paraneoplastic neurological syndromes: the utility (or futility) of rare antibody discovery. Curr. Opin. Neurol. (IF 4.8) Pub Date : 2024-03-27 Yahel Segal, Anastasia Zekeridou
The increasing recognition and diagnosis of autoimmune encephalitis (AE) and paraneoplastic neurological syndromes (PNS) is partly due to neural autoantibody testing and discovery. The past two decades witnessed an exponential growth in the number of identified neural antibodies. This review aims to summarize recent rare antibody discoveries in the context of central nervous system (CNS) autoimmunity
-
Targeting Epstein-Barr virus in multiple sclerosis: when and how? Curr. Opin. Neurol. (IF 4.8) Pub Date : 2024-03-22 Gavin Giovannoni
Epidemiological evidence implicates Epstein-Barr virus (EBV) as the cause of multiple sclerosis (MS). However, its biological role in the pathogenesis of MS is uncertain. The article provides an overview of the role of EBV in the pathogenesis of MS and makes a case for targeting EBV as a treatment strategy for MS.
-
Current opinion: Racial and ethnic health disparities in multiple sclerosis: considering the social determinants of health. Curr. Opin. Neurol. (IF 4.8) Pub Date : 2024-03-21 Michael V Robers, Lilyana Amezcua
We discuss racial and ethnic disparities in multiple sclerosis (MS), outcomes, and social determinants of health (SDoH). We also provide essential considerations needed to bridge the gap in inequalities, including broader representation of racial and ethnic people in clinical trials and research in general and the inclusion of better measures of living conditions.
-
Clinical characteristics of patients with myelin oligodendrocyte glycoprotein antibodies. Curr. Opin. Neurol. (IF 4.8) Pub Date : 2024-03-19 Elisabeth Maillart, Kumaran Deiva, Romain Marignier
The clinical landscape associated to myelin oligodendrocyte glycoprotein antibodies (MOG-Ab) has undergone a remarkable transformation over the past two decades, primarily driven by advancements in antibody detection techniques that have enhanced both the specificity and sensitivity of assays, enabling the identification of novel clinical phenotypes.
-
Central nervous system adverse events of immune checkpoint inhibitors. Curr. Opin. Neurol. (IF 4.8) Pub Date : 2024-03-15 Antonio Farina, Macarena Villagrán-García, Alberto Vogrig, Bastien Joubert
Immune checkpoint inhibitors (ICI) may trigger immune-related adverse events which rarely affect the central nervous system (CNS-irAEs). Over the past few years, cumulative data have led to the characterization of well defined syndromes with distinct cancer and antibody associations as well as different outcomes.
-
Neuronal antibodies in nonparaneoplastic autoimmune cerebellar ataxias. Curr. Opin. Neurol. (IF 4.8) Pub Date : 2024-03-15 Albert Saiz, Francesc Graus
To describe relevant advances in nonparaneoplastic autoimmune cerebellar ataxias (ACA) with neuronal antibodies.
-
Genetic predisposition to autoimmune encephalitis and paraneoplastic neurological syndromes. Curr. Opin. Neurol. (IF 4.8) Pub Date : 2024-03-15 Sergio Muñiz-Castrillo, Jérôme Honnorat
We summarize the recent discoveries on genetic predisposition to autoimmune encephalitis and paraneoplastic neurological syndromes (PNS), emphasizing clinical and pathophysiological implications.
-
Visual snow syndrome: recent advances in understanding the pathophysiology and potential treatment approaches. Curr. Opin. Neurol. (IF 4.8) Pub Date : 2024-03-12 Sarah A Aeschlimann, Antonia Klein, Christoph J Schankin
Visual snow syndrome (VSS) is a disorder characterized by persistent visual disturbances, including the visual snow phenomenon, palinopsia, heightened perception of entoptic phenomena, impaired night vision, and photophobia. The purpose of this review is to provide an update on recent findings over the past 18 months in VSS research and to summarize the current state of treatment approaches.
-
Glymphatic system dysfunction in neurodegenerative diseases. Curr. Opin. Neurol. (IF 4.8) Pub Date : 2024-02-13 Natalie Beschorner, Maiken Nedergaard
Purpose of this review is to update the ongoing work in the field of glymphatic and neurodegenerative research and to highlight focus areas that are particularly promising.
-
Prevention of epileptogenesis - are we there yet? Curr. Opin. Neurol. (IF 4.8) Pub Date : 2024-02-13 Matthias Koepp, Eugen Trinka, Wolfgang Löscher, Pavel Klein
To review recent progress in preventing epileptogenesis in patients with epilepsy.
-
Evidence based noninvasive presurgical evaluation for patients with drug resistant epilepsies. Curr. Opin. Neurol. (IF 4.8) Pub Date : 2024-02-12 Eugen Trinka, Matthias Koepp, Gudrun Kalss, Teia Kobulashvili
To review the current practices and evidence for the diagnostic accuracy and the benefits of presurgical evaluation.
-
The role of caffeine in headache disorders. Curr. Opin. Neurol. (IF 4.8) Pub Date : 2024-02-08 Andrew Charles
Caffeine is known to have both beneficial and adverse effects in individuals with headache disorders. This review describes recent findings regarding caffeine that are relevant to headache disorders and puts these findings into the context of clinical management.
-
Ambulatory seizure detection. Curr. Opin. Neurol. (IF 4.8) Pub Date : 2024-02-08 Adriano Bernini, Jonathan Dan, Philippe Ryvlin
To review recent advances in the field of seizure detection in ambulatory patients with epilepsy.
-
Posttraumatic headache is a distinct headache type from migraine. Curr. Opin. Neurol. (IF 4.8) Pub Date : 2024-02-01 Keiko Ihara, Todd J Schwedt
Posttraumatic headache (PTH), a headache that develops within 7 days of a causative injury, is one of the most common secondary headaches, mostly attributed to mild traumatic brain injury (mTBI). Because presence of preinjury headache is a risk factor for developing PTH and PTH symptoms often resemble migraine or tension-type headache, the association between PTH and primary headaches has attracted
-
Update on modifiable risk factors for Alzheimer's disease and related dementias. Curr. Opin. Neurol. (IF 4.8) Pub Date : 2024-01-25 Methasit Jaisa-Aad, Clara Muñoz-Castro, Alberto Serrano-Pozo
All human beings undergo a lifelong cumulative exposure to potentially preventable adverse factors such as toxins, infections, traumatisms, and cardiovascular risk factors, collectively termed exposome. The interplay between the individual's genetics and exposome is thought to have a large impact in health outcomes such as cancer and cardiovascular disease. Likewise, a growing body of evidence is supporting
-
Somatic mosaicism in focal epilepsies. Curr. Opin. Neurol. (IF 4.8) Pub Date : 2024-01-19 Samuel Gooley, Piero Perucca, Caitlin Tubb, Michael S Hildebrand, Samuel F Berkovic
Over the past decade, it has become clear that brain somatic mosaicism is an important contributor to many focal epilepsies. The number of cases and the range of underlying pathologies with somatic mosaicism are rapidly increasing. This growth in somatic variant discovery is revealing dysfunction in distinct molecular pathways in different focal epilepsies.
-
Recent advances in Alzheimer disease genetics. Curr. Opin. Neurol. (IF 4.8) Pub Date : 2024-01-19 Gaël Nicolas
Genetics studies provide important insights into Alzheimer disease (AD) etiology and mechanisms. Critical advances have been made recently, mainly thanks to the access to novel techniques and larger studies.
-
An update on psychogenic nonepileptic seizures. Curr. Opin. Neurol. (IF 4.8) Pub Date : 2024-01-19 Mithila Vijay, Markus Reuber
The understanding of psychogenic nonepileptic seizures (PNES) has advanced steadily over recent decades. This update summarizes new insights from the last three years.
-
Recent advances in clinical electroencephalography. Curr. Opin. Neurol. (IF 4.8) Pub Date : 2024-01-18 Birgit Frauscher, Andrea O Rossetti, Sándor Beniczky
Clinical electroencephalography (EEG) is a conservative medical field. This explains likely the significant gap between clinical practice and new research developments. This narrative review discusses possible causes of this discrepancy and how to circumvent them. More specifically, we summarize recent advances in three applications of clinical EEG: source imaging (ESI), high-frequency oscillations
-
Predictive models of epilepsy outcomes. Curr. Opin. Neurol. (IF 4.8) Pub Date : 2024-01-16 Shehryar Sheikh, Lara Jehi
Multiple complex medical decisions are necessary in the course of a chronic disease like epilepsy. Predictive tools to assist physicians and patients in navigating this complexity have emerged as a necessity and are summarized in this review.
-
Revascularization of arterial occlusions in posterior circulation acute ischemic stroke. Curr. Opin. Neurol. (IF 4.8) Pub Date : 2023-12-13 Alexander Salerno, Patrik Michel, Davide Strambo
This review highlights the latest advancements achieved in the revascularization of arterial occlusions associated with an acute ischemic stroke affecting the posterior circulation. It delves into the frequency and outcomes based on specific arterial segments and presents current evidence supporting revascularization treatments, including intravenous thrombolysis and endovascular thrombectomy.
-
Is thrombectomy indicated in all ischemic stroke with large vessel occlusion? Curr. Opin. Neurol. (IF 4.8) Pub Date : 2023-12-07 Deep K Pujara, Faisal Al-Shaibi, Amrou Sarraj
Purpose of this topical review is to examine the current randomized and nonrandomized evidence evaluating endovascular thrombectomy (EVT) in selected patient populations with acute ischemic stroke due to large vessel occlusions.
-
In-vivo diagnosis of cerebral amyloid angiopathy: an updated review. Curr. Opin. Neurol. (IF 4.8) Pub Date : 2023-12-04 Nicolas Raposo, Charlotte Périole, Mélanie Planton
Sporadic cerebral amyloid angiopathy (CAA) is a highly prevalent small vessel disease in ageing population with potential severe complications including lobar intracerebral hemorrhage (ICH), cognitive impairment, and dementia. Although diagnosis of CAA was made only with postmortem neuropathological examination a few decades ago, diagnosing CAA without pathological proof is now allowed in living patients
-
Does imaging of the ischemic penumbra have value in acute ischemic stroke with large vessel occlusion? Curr. Opin. Neurol. (IF 4.8) Pub Date : 2023-12-04 Pierre Seners, Jean-Claude Baron, Jean-Marc Olivot, Gregory W Albers
In this review, we summarize current evidence regarding potential benefits and limitations of using perfusion imaging to estimate presence and extent of irreversibly injured ischemic brain tissue ('core') and severely ischemic yet salvageable tissue ('penumbra') in acute stroke patients with large vessel occlusion (LVO).
-
Aging of the vestibular system and its relationship to dementia. Curr. Opin. Neurol. (IF 4.8) Pub Date : 2023-12-01 Paul F Smith
Since October 2022, substantial new information has been published on age-related effects on the vestibular system. Since much of this evidence relates to the risk of dementia, the purpose of this review will be to provide an overview of this new information and critically evaluate it.
-
Central vestibular networking for sensorimotor control, cognition, and emotion. Curr. Opin. Neurol. (IF 4.8) Pub Date : 2023-12-01 Marianne Dieterich, Thomas Brandt
The aim of this study was to illuminate the extent of the bilateral central vestibular network from brainstem and cerebellum to subcortical and cortical areas and its interrelation to higher cortical functions such as spatial cognition and anxiety.
-
Vascular neuro-otology: vestibular transient ischemic attacks and chronic dizziness in the elderly. Curr. Opin. Neurol. (IF 4.8) Pub Date : 2023-12-01 Adolfo M Bronstein, Jorge Kattah
To explore the differential diagnosis of posterior fossa transient ischemic attacks (TIA) associated with vertigo and/or imbalance.To review the contribution of cerebral small vessel (SVD) disease to balance dysfunction and dizziness in the elderly.
-
What visuospatial perception has taught us about the pathophysiology of vestibular migraine. Curr. Opin. Neurol. (IF 4.8) Pub Date : 2023-11-30 Qadeer Arshad, David Moreno-Ajona, Peter J Goadsby, Amir Kheradmand
: A decade has passed since vestibular migraine (VM) was formally established as a clinical entity. During this time, VM has emerged amongst the most common cause of episodic vertigo. Like all forms of migraine, VM symptoms are most prominent during individual attacks, however many patients may also develop persistent symptoms that are less prominent and can still interfere with daily activities.
-
Vestibular contribution to spatial orientation and navigation. Curr. Opin. Neurol. (IF 4.8) Pub Date : 2023-11-28 Andreas Zwergal, Denis Grabova, Florian Schöberl
The vestibular system provides three-dimensional idiothetic cues for updating of one's position in space during head and body movement. Ascending vestibular signals reach entorhinal and hippocampal networks via head-direction pathways, where they converge with multisensory information to tune the place and grid cell code.
-
Editorial: Update on current topics in spinal cord injury, trauma and rehabilitation. Curr. Opin. Neurol. (IF 4.8) Pub Date : 2023-11-09 Ona Bloom,James Guest
-
Editorial: Advances in basic science and technology are bringing new flavor in neuro-oncology. Curr. Opin. Neurol. (IF 4.8) Pub Date : 2023-11-09 Riccardo Soffietti
-
Review of spinal cord stimulation for disorders of consciousness. Curr. Opin. Neurol. (IF 4.8) Pub Date : 2023-10-27 Guilherme Santos Piedade, Bernardo Assumpcao de Monaco, James D Guest, Joacir Graciolli Cordeiro
High-cervical spinal cord stimulation can alter cortical activity and cerebral metabolism. These effects are potentially beneficial for disorders of consciousness. A better understanding of the effects of clinical application of stimulation is needed. We aimed to evaluate the existing literature to determine the state of available knowledge. We performed a literature review of clinical studies assessing
-
Electrical stimulation of the peripheral and central vestibular system. Curr. Opin. Neurol. (IF 4.8) Pub Date : 2023-10-26 Christophe Lopez, Kathleen E Cullen
Electrical stimulation of the peripheral and central vestibular system using noninvasive (galvanic vestibular stimulation, GVS) or invasive (intracranial electrical brain stimulation, iEBS) approaches have a long history of use in studying self-motion perception and balance control. The aim of this review is to summarize recent electrophysiological studies of the effects of GVS, and functional mapping
-
Epidemiology and genetics of Meniere's disease. Curr. Opin. Neurol. (IF 4.8) Pub Date : 2023-10-23 Jose A Lopez-Escamez, Ying Liu
This review discusses the recent developments on the understanding of epidemiology and genetics of Meniere's disease.
-
Vestibular syncope. Curr. Opin. Neurol. (IF 4.8) Pub Date : 2023-10-19 Jeong-Yoon Choi, Eek-Sung Lee, Ji-Soo Kim
This review considers recent observations on vestibular syncope in terms of clinical features, laboratory findings, and potential mechanisms.
-
Primary central nervous system vasculitis and headache: Ten themes. Curr. Opin. Neurol. (IF 4.8) Pub Date : 2023-10-17 David S Younger
The primary central nervous system (CNS) vasculitides refers to clinicopathologic disorders that share the histopathology of inflammation of cerebral or spinal blood vessels. Unrecognized and therefore untreated, vasculitis of the CNS results in irreversible injury and disability making these disorders of paramount importance to clinicians.
-
Vasculitis and headache. Part 1: systemic vasculitis. Curr. Opin. Neurol. (IF 4.8) Pub Date : 2023-10-13 David S Younger
Vasculitis refers to heterogeneous clinicopathologic disorders that share the histopathology of inflammation of blood vessels. Unrecognized and therefore untreated, vasculitis of the nervous system or so called neurovasculitides, lead to pervasive injury and disability making these disorder of paramount importance to clinicians.
-
Combination of radiosurgery and immunotherapy in brain metastases: balance between efficacy and toxicities. Curr. Opin. Neurol. (IF 4.8) Pub Date : 2023-10-05 Angela Botticella, Frederic Dhermain
The incidence of brain metastasis is high and still increasing. Among local therapies, stereotactic radiosurgery (SRS) is an effective treatment option, optimally sparing normal brain, even for multiple brain metastases. Immune checkpoint inhibitors (ICIs) become the new standard of care in an increasing number of cancers, and the combination SRS and ICI is often proposed to patients, but few data
-
Clinical impact of molecular profiling in rare brain tumors. Curr. Opin. Neurol. (IF 4.8) Pub Date : 2023-10-04 Drew Pratt, Marta Penas-Prado, Mark R Gilbert
The purpose of this review is to describe the commonly used molecular diagnostics and illustrate the prognostic importance to the more accurate diagnosis that also may uncover therapeutic targets.
-
COVID-19 related headaches: epidemiology, pathophysiology, impacts, and management. Curr. Opin. Neurol. (IF 4.8) Pub Date : 2023-10-04 Olalekan Lee Aiyegbusi
This is an expert overview of the recent literature on the nature, epidemiology, pathophysiology, impact, and management of COVID-19 related headache, in the acute phase of infection and in post-COVID-19 syndrome.
-
Novel approaches to treatment of leptomeningeal metastases. Curr. Opin. Neurol. (IF 4.8) Pub Date : 2023-10-04 Ditte Primdahl, Adam Cohen-Nowak, Priya Kumthekar
The incidence of leptomeningeal metastases is increasing in the setting of improved survival from systemic cancers. In more recent years, our understanding of leptomeningeal metastasis pathogenesis, how to diagnose and treat has been evolving.
-
Remote Ischemic conditioning as an emerging tool to improve corticospinal transmission in individuals with chronic spinal cord injury. Curr. Opin. Neurol. (IF 4.8) Pub Date : 2023-10-02 Yu-Kuang Wu, Jill M Wecht, Ona E Bloom, Gino S Panza, Noam Y Harel
Remote ischemic conditioning (RIC) involves transient blood flow restriction to one limb leading to systemic tissue-protective effects. RIC shares some potential underlying mechanisms with intermittent hypoxia (IH), in which brief bouts of systemic hypoxia trigger increases in growth factor expression and neural plasticity. RIC has shown promise in acute myocardial infarction and stroke but may be
-
Epilepsy in gliomas: recent insights into risk factors and molecular pathways. Curr. Opin. Neurol. (IF 4.8) Pub Date : 2023-10-02 Roberta Rudà, Francesco Bruno, Alessia Pellerino
The purpose of this review is to discuss the molecular pathways governing the development of seizures in glioma patients.
-
Editorial:Framing artificial intelligence to neuromuscular disorders. Curr. Opin. Neurol. (IF 4.8) Pub Date : 2023-10-01 Benedikt Schoser
-
Editorial: Neuromuscular diseases: differential diagnosis and targeted treatment. Curr. Opin. Neurol. (IF 4.8) Pub Date : 2023-10-01 Claudia Sommer
-
How to evaluate extent of resection in diffuse gliomas: from standards to new methods. Curr. Opin. Neurol. (IF 4.8) Pub Date : 2023-09-29 Nico Teske, Joerg-Christian Tonn, Philipp Karschnia
Maximal safe tumor resection represents the current standard of care for patients with newly diagnosed diffuse gliomas. Recent efforts have highlighted the prognostic value of extent of resection measured as residual tumor volume in patients with isocitrate dehydrogenase (IDH)-wildtype and -mutant gliomas. Accurate assessment of such information therefore appears essential in the context of clinical
-
Idiopathic intracranial hypertension: expanding our understanding. Curr. Opin. Neurol. (IF 4.8) Pub Date : 2023-09-29 Keira Markey, Christopher Hutchcroft, Hedley Emsley
Idiopathic intracranial hypertension (IIH) affects predominantly overweight women of childbearing age, causing chronically disabling headaches and visual loss. Weight loss remains the most effective management strategy, but innovative treatments and randomized control trials (RCTs) remain few. This paper will review recent IIH research.
-
Novel trial designs in neuro-oncology. Curr. Opin. Neurol. (IF 4.8) Pub Date : 2023-09-29 Kun-Wei Song, Patrick Y Wen
An important factor contributing to the low rate of success in identifying effective therapies for brain tumor patients is the slow, inefficient, and expensive process of drug development, as well as small patient numbers, low patient participation in clinical trials, and reluctance of patients to enroll in ineffective control arms. In recent years, a number of novel trial designs have been developed
-
Assessing the efficacy of duration and intensity prescription for physical activity in mitigating cardiometabolic risk after spinal cord injury. Curr. Opin. Neurol. (IF 4.8) Pub Date : 2023-09-27 Gary J Farkas, Lizeth J Caldera, Mark S Nash
Spinal cord injury (SCI) heightens susceptibility to cardiometabolic risk (CMR), predisposing individuals to cardiovascular disease. This monograph aims to assess the optimal duration and intensity of physical activity (PA) for managing CMR factors, particularly obesity, after SCI and provide modality-specific PA durations for optimal energy expenditure.
-
Neuroscience and oncology: state-of-the-art and new perspectives. Curr. Opin. Neurol. (IF 4.8) Pub Date : 2023-09-26 Frank Winkler
Emerging discoveries suggest that both the central (CNS) and peripheral (PNS) nervous system are an important driver of cancer initiation, promotion, dissemination, and therapy resistance, not only in the brain but also in multiple cancer types throughout the body. This article highlights the most recent developments in this emerging field of research over the last year and provides a roadmap for the
-
Artificial intelligence in neuroimaging of brain tumors: reality or still promise? Curr. Opin. Neurol. (IF 4.8) Pub Date : 2023-09-26 Ian Pan, Raymond Y Huang
To provide an updated overview of artificial intelligence (AI) applications in neuro-oncologic imaging and discuss current barriers to wider clinical adoption.
-
Vagal nerve stimulation for headache. Curr. Opin. Neurol. (IF 4.8) Pub Date : 2023-09-26 Srikant Venkatakrishnan, Pravin Thomas
Vagal nerve stimulation (VNS) is emerging as a probable therapeutic option for headache. Several questions remain on the mechanism of action, device parameters, efficacy, duration of treatment and long-term safety. This review aims at describing findings of recent literature pertaining to VNS for headache, to put these findings into the perspective of our current fund of knowledge and future scope
-
Development of neural repair therapy for chronic spinal cord trauma: soluble nogo receptor decoy from discovery to clinical trial. Curr. Opin. Neurol. (IF 4.8) Pub Date : 2023-09-20 Elisa M Howard, Stephen M Strittmatter
After traumatic spinal cord injury (SCI), neurological deficits persist due to the disconnection of surviving neurons. While repair of connectivity may restore function, no medical therapy exists today.This review traces the development of the neural repair-based therapeutic AXER-204 from animal studies to the recent clinical trial for chronic cervical SCI.